HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma.
Gallbladder carcinoma (GBC) is an aggressive type of cancer with a dismal prognosis. Recent case reports have highlighted the human epidermal growth factor receptor 2 (HER2) as a promising target for individualized therapy in biliary tract cancer; however, current data on HER2 positivity in GBC is c...
| Publicado en: | Virchows Archiv: European Journal of Pathology Vol. 476; no. 6; pp. 871 - 881 |
|---|---|
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
| Formato: | Journal Article |
| Publicado: |
Springer Nature
Jun2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=143593673&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 143593673 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09456317 O1Z jtl: Virchows Archiv: European Journal of Pathology issn: 09456317 maglogo: N pubinfo: dt: Jun2020 vid: 476 iid: 6 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 143593673 143593673 NLM31838585 10.1007/s00428-019-02706-6 NLM31838585 143593673 ppf: 871 ppct: 10 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: HER2 gene (ERBB2) amplification is a low-frequency driver with potential predictive value in gallbladder carcinoma. aug: au: Albrecht, Thomas Rausch, Melina Roessler, Stephanie Geissler, Veronika Albrecht, Michael Halske, Christine Seifert, Carolin Renner, Marcus Singer, Stephan Mehrabi, Arianeb Vogel, Monika Nadja Pathil-Warth, Anita Busch, Elena Köhler, Bruno Rupp, Christian Weiss, Karl Heinz Springfeld, Christoph Röcken, Christoph Schirmacher, Peter Goeppert, Benjamin affil: Institute of Pathology, Heidelberg University Hospital, Im Neuenheimer Feld 224, 69120, Heidelberg, Germany sug: subj: Adenocarcinoma Diagnosis Receptors, Cell Surface Gallbladder Neoplasms Diagnosis Prospective Studies Female Aged Gallbladder Neoplasms Middle Age Germany Male Prognosis Aged, 80 and Over Gallbladder Neoplasms Pathology Adenocarcinoma In Situ Hybridization Adenocarcinoma Pathology Predictive Value of Tests Immunohistochemistry Gene Amplification Scales Aged: 65+ years Middle Aged: 45-64 years Aged, 80 & over Female Male ab: Gallbladder carcinoma (GBC) is an aggressive type of cancer with a dismal prognosis. Recent case reports have highlighted the human epidermal growth factor receptor 2 (HER2) as a promising target for individualized therapy in biliary tract cancer; however, current data on HER2 positivity in GBC is contradictory. This study aimed to assess the proportion of HER2 positivity and its clinical implications in a large and well-characterized European GBC cohort. HER2 status was determined in 186 cases of surgically resected gallbladder adenocarcinoma and a subset of coexistent high-grade biliary intraepithelial neoplasia (BilIN, n = 74) in accordance with the up-to-date consensus for HER2 testing in gastric cancer by immunohistochemistry and dual-color chromogenic in situ hybridization. Positivity for HER2 was observed in 5.4% of all cases (n = 10). In those patients with concomitant high-grade BilIN, two of four positive samples also showed amplification in the precursor lesion, while in the two remaining cases, positivity was either confined to invasive tumor or high-grade BilIN, exclusively. Equivocal staining found in eleven cases was not accompanied by gene amplification. Staging of the HER2-positive group was significantly different from the HER2-negative group with most cases presenting at stage IV, paralleled by a trend towards decreased survival. One patient who received dual HER2 inhibition almost went into full clinical remission despite treatment initiation in a metastasized state. Our results reveal a low prevalence of HER2 positivity and highlight HER2 gene amplification as an early, potentially driving event in gallbladder carcinogenesis. Prospective standardized HER2 testing and randomized control studies are needed to prove clinical efficacy of targeted HER2 inhibition in GBC. pubtype: Academic Journal doctype: Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|